5
Participants
Start Date
April 30, 2016
Primary Completion Date
September 30, 2020
Study Completion Date
September 30, 2020
LEE011
600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
Chemoembolization
Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
UT Southwestern Medical Center, Dallas
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
University of Texas Southwestern Medical Center
OTHER